Organon & Co. (0A9W)
LSE
Closed
Aug 21, 2026
Day's Range
13.7352 wk Range
5.71Overview - 0A9W - Organon & Co.
Key Statistics
Valuation
Enterprise Value
12.50B
P/E (Trailing)
‪3.14‬
PEG Ratio
‪-0.11‬
Price / Sales (TTM)
‪0.41‬
Price / Book
‪3.58‬
EV / EBITDA
‪7.28‬
Profitability
Gross Margin
‪54.36%‬
Profit Margin
‪12.22%‬
Operating Margin
‪24.18%‬
Return on Assets
‪8.63%‬
Return on Equity
‪24.86%‬
Ownership
Shares Outstanding
262.60M
Float
255.16M
Held by Insiders
‪0.10%‬
Held by Institutions
‪79.76%‬
Price stats
Beta
‪0.87‬
50-Day Avg
‪13.54‬
200-Day Avg
‪10.01‬
Dividends
Payout Ratio
‪37.97%‬
Frequency
Quarterly
Market Cap - 0A9W - Organon & Co.
Peers - 0A9W - Organon & Co.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on LSE.
- 0A9WLSEOrganon & Co.3.79BMarket Cap+33.88%52-week change3.14P/E (Trailing)‪12.22%‬Profit Margin
- AZNLSEAstraZeneca PLC18.78TMarket Cap+1.97%52-week change24.98P/E (Trailing)‪17.02%‬Profit Margin
- GSKLSEGSK plc7.68TMarket Cap+23.02%52-week change16.26P/E (Trailing)‪14.52%‬Profit Margin
- 0QIULSENovo Nordisk A/S1.24TMarket Cap-23.24%52-week change19.95P/E (Trailing)‪33.39%‬Profit Margin
- 0Q1GLSEEli Lilly and Company686.33BMarket Cap+54.90%52-week change1.56P/E (Trailing)‪33.52%‬Profit Margin
- 0QCVLSEAbbVie Inc.478.52BMarket Cap+21.83%52-week change54.73P/E (Trailing)‪15.50%‬Profit Margin
- 0QAHLSEMerck & Co., Inc.383.85BMarket Cap+44.02%52-week change63.23P/E (Trailing)‪5.33%‬Profit Margin
Profile Summary - 0A9W - Organon & Co.
About
Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
